New LaunchAug 12, 2026, 08:06 AM
Scienture Launches REZENOPY™ Naloxone Nasal Spray 10 mg
AI Summary
Scienture Holdings, Inc. announced the commercial launch of REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg, its second FDA-approved commercial product. This high-dose naloxone nasal spray targets the approximately $143 million U.S. naloxone market, fulfilling initial purchase orders to wholesalers. The launch is supported by a national sales force, payer coverage for over 100 million lives, and GPO agreements providing access to more than 5,000 healthcare facilities, aiming to maximize its commercial potential.
Key Highlights
- Commercial launch of REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg.
- REZENOPY™ is Scienture's second FDA-approved commercial product.
- It is the highest-dose FDA-approved naloxone hydrochloride nasal spray in the U.S.
- U.S. naloxone market is approximately $143 million annually.
- Payer coverage represents potential to reach over 100 million covered lives.
- GPO agreements provide access to over 5,000 healthcare facilities.
- FDA approval for REZENOPY™ was received on April 19, 2024.
Price Impact
More from SCNX